Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal

Executive Summary

CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.

You may also be interested in...

CMS Drops Proposal To Change Part D Protected Drug Classes

In a letter to Congress, CMS Administrator Tavenner says that due to strong opposition from members of Congress and stakeholders, it will not finalize several controversial proposals in its recent draft rule for Medicare Part D, including removal of special formulary protection for three drug classes.

CMS’ Blum Will Respond To Criticism Of Part D Proposed Rule At House Hearing

The Energy & Commerce Health Subcommittee plans a Feb. 26 hearing to air members’ opposition to CMS’ proposed rule on Medicare Part D, and Republicans warn that failure to “reject” the proposed rule “will force Congress to evaluate all legislative options necessary to ensure seniors are protected.”

CMS Part D Proposal Is “Solution In Search Of A Problem” – PhRMA’s Castellani

PhRMA CEO John Castellani explains in an interview why Medicare Part D stakeholders are united in the concern that the sweeping changes proposed by CMS will “harm patients, limit choice and ultimately will raise costs in a program that by any measure is working well.”

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts